Tobii Dynavox AB (publ) (TDVXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tobii Dynavox AB (publ) (TDVXF) trades at $6.45 with AI Score 56/100 (Grade B). Tobii Dynavox AB (publ) is a global leader in assistive communication technology, providing speech-generating devices and eye-tracking systems for individuals with disabilities. Market cap: $684.12M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for TDVXF: TDVXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TDVXF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TDVXF: 1/4 perspectives are bullish. Dominant signal: Moon AI bullish.
How is this calculated? →Tobii Dynavox AB (publ) (TDVXF) Healthcare & Pipeline Overview
Tobii Dynavox AB (publ) is a global leader in assistive technology, specializing in augmentative and alternative communication (AAC) solutions for individuals with disabilities. The company develops and distributes advanced speech-generating devices and eye-tracking systems, alongside comprehensive software and accessories, establishing a significant presence in the medical instruments and supplies industry.
What Is the Investment Thesis for TDVXF?
Tobii Dynavox AB (publ) presents a research focus centered on its established leadership in the specialized augmentative and alternative communication (AAC) market, underpinned by a robust gross margin of 68.2% and a profit margin of 7.3%. The company's market capitalization of $684.12M reflects its significant presence in the medical instruments and supplies sector. Key value drivers include the increasing global demand for assistive technologies driven by an aging population and rising awareness of communication disabilities. Growth catalysts involve continuous innovation in eye-tracking and speech-generating device technologies, expansion into emerging markets, and potential partnerships with healthcare providers to integrate AAC solutions more broadly into rehabilitation programs. The company's beta of 0.77 suggests lower volatility relative to the broader market, which may appeal to certain investor profiles. However, potential risk factors include intense competition from alternative communication methods and lower-cost solutions, alongside the need to adapt to rapid technological advancements in the accessibility space to maintain market share. Monitoring the company's R&D investments and market penetration strategies will be crucial for assessing its long-term trajectory.
Based on FMP financials and quantitative analysis
TDVXF Key Highlights
- Market Capitalization: $0.80 billion, reflecting its valuation in the specialized medical instruments and supplies sector.
- Gross Margin: 68.2%, indicating strong profitability on its core assistive technology products and services.
- Profit Margin: 7.3%, demonstrating efficient management of operational costs relative to its revenue.
- P/E Ratio: 41.80, suggesting investor expectations for future growth in its niche market.
- Employee Base: 875 employees globally, supporting its research, development, and distribution efforts.
Who Are TDVXF's Competitors?
TDVXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| ISRG Intuitive Surgical, Inc. | $432.83 | +1.60% | $153.29B | 56 |
| HOCPY HOYA Corporation | $158.60 | +0.48% | $53.05B | 56 |
| ANSLY Ansell Limited | $81.94 | -2.56% | $2.89B | 56 |
| SMTI Sanara MedTech Inc. | $24.48 | -1.47% | $224.29M | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TDVXF's Key Strengths?
- Global leadership and strong brand recognition in the AAC market.
- Comprehensive product portfolio including hardware, software, and accessories.
- High gross margin (68.2%) indicates strong product profitability.
- Established R&D capabilities in eye-tracking and speech-generating technologies.
What Are TDVXF's Weaknesses?
- Relatively high P/E ratio (41.80) may indicate high growth expectations.
- Potential reliance on specialized niche market, limiting broader market appeal.
- "Unknown" OTC disclosure status could imply limited transparency for investors.
- Potential for high R&D costs to maintain technological edge.
What Could Drive TDVXF Stock Higher?
- Regulatory Approvals for New Devices: Successful navigation and approval of new or upgraded assistive technology devices in key markets (e.g., US, EU) could significantly expand market access and sales potential.
- Technological Advancements in AAC: Continuous innovation in eye-tracking precision, AI-driven speech synthesis, and software integration will enhance product appeal and maintain competitive edge.
- Strategic Partnerships: Formation of new collaborations with major healthcare providers, insurance companies, or educational networks could accelerate market penetration and adoption rates.
- Geographic Market Expansion: Successful entry and growth in new international markets, particularly emerging economies with increasing healthcare access, could drive revenue diversification.
What Are the Key Risks for TDVXF?
- Rich valuation — a P/E of 36.9 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Intense Competition: The market for assistive communication faces ongoing competition from both specialized AAC providers and broader technology companies offering alternative, potentially lower-cost, communication solutions.
- Regulatory Changes: Evolving healthcare regulations and reimbursement policies in key markets could impact product pricing, market access, and profitability for assistive devices.
- Rapid Technological Obsolescence: The fast pace of technological change in areas like AI, eye-tracking, and mobile computing necessitates continuous R&D investment to avoid product obsolescence.
- Supply Chain Disruptions: Reliance on global supply chains for components could expose the company to risks from geopolitical events, natural disasters, or manufacturing delays, impacting production and delivery.
- Data Security and Privacy Concerns: As devices collect and process sensitive user data, any breaches or failures in data security could lead to reputational damage, regulatory fines, and loss of customer trust.
What Are the Growth Opportunities for TDVXF?
- Expansion into Emerging Markets: The global market for assistive technologies, particularly AAC, is experiencing increased awareness and demand in developing regions. Tobii Dynavox can leverage its established product portfolio and brand reputation to enter these underserved markets, potentially through strategic partnerships with local distributors or healthcare organizations. This expansion could tap into a significant user base, as accessibility infrastructure and support systems improve globally, representing a substantial long-term growth vector over the next 5-10 years. The market size for assistive technologies in these regions is projected to grow significantly as healthcare access expands.
- Integration of Advanced AI and Machine Learning: The continuous evolution of artificial intelligence and machine learning offers substantial opportunities to enhance AAC solutions. Tobii Dynavox can integrate more sophisticated AI for improved natural language processing, predictive text, personalized voice synthesis, and context-aware communication. This would make devices more intuitive and efficient, potentially expanding their appeal to a wider range of users and use cases. Such advancements could lead to new product cycles and upgrades, driving revenue growth over the next 3-7 years, as the global AI in healthcare market is expected to reach hundreds of billions of dollars.
- Partnerships with Healthcare Providers and Educational Institutions: Expanding collaborations with hospitals, rehabilitation centers, and educational systems presents a significant growth avenue. By integrating its AAC solutions into standard care pathways and special education curricula, Tobii Dynavox can increase adoption rates and establish long-term relationships. These partnerships can facilitate broader awareness, training, and reimbursement for its products. This strategy could solidify market penetration and create a steady demand stream over the next 5-10 years, tapping into institutional budgets and professional recommendations.
- Development of Specialized Software and Mobile Applications: While Tobii Dynavox already offers software, there is an ongoing opportunity to develop more specialized applications tailored to specific conditions or therapeutic areas, or to integrate with broader smart home and IoT ecosystems. This could include apps for cognitive training, advanced data analytics for therapists, or seamless integration with other assistive smart devices. This focus on software innovation can create recurring revenue streams through subscriptions and expand the utility of existing hardware, appealing to a tech-savvy user base. This growth could materialize over the next 2-5 years, as the digital health market continues its rapid expansion.
- Enhanced Eye-Tracking Technology for Broader Applications: Tobii Dynavox's expertise in eye-tracking technology extends beyond communication. There is an opportunity to enhance and adapt this technology for broader applications within the assistive tech space, such as environmental control, advanced gaming for individuals with motor impairments, or even diagnostic tools for neurological conditions. Investing in R&D to push the boundaries of eye-tracking precision and versatility could open up entirely new market segments and revenue streams, leveraging its core competency. This represents a longer-term growth opportunity, potentially impacting the company's trajectory over the next 7-15 years.
What Opportunities Does TDVXF Have?
- Growing global demand for assistive technologies due to aging populations and increased awareness.
- Integration of advanced AI/ML for enhanced communication features.
- Expansion into new geographic markets and therapeutic areas.
- Partnerships with healthcare systems and educational bodies for broader adoption.
What Threats Does TDVXF Face?
- Increasing competition from alternative communication methods and lower-cost solutions.
- Rapid technological advancements requiring continuous investment to stay competitive.
- Potential changes in healthcare reimbursement policies affecting device affordability.
- Economic downturns impacting discretionary spending on specialized medical devices.
What Are TDVXF's Competitive Advantages?
- Specialized Technology and R&D: Deep expertise in eye-tracking and speech-generating device technology, built over decades, creating high barriers to entry for new competitors.
- Established Brand Recognition: Strong reputation and trust within the augmentative and alternative communication (AAC) market among users, professionals, and institutions.
- Comprehensive Ecosystem: Offers a full suite of integrated hardware, software, and accessories, providing a complete solution rather than fragmented components.
- Global Distribution and Support: Extensive reach and support infrastructure catering to a specialized global customer base, which is difficult for smaller players to replicate.
- Regulatory Compliance and Clinical Validation: Products often require rigorous testing and regulatory approvals, building credibility and ensuring market access.
What Does TDVXF Do?
Tobii Dynavox AB (publ), established in 1983 and headquartered in Danderyd, Sweden, has evolved into a global leader in the development and distribution of assistive technology. The company's core mission is to empower individuals with disabilities by enhancing their communication capabilities through innovative solutions. Tobii Dynavox delivers a comprehensive portfolio of augmentative and alternative communication (AAC) products, which are crucial for users who cannot rely on verbal speech. This extensive range includes advanced speech-generating devices that translate user input into spoken words, and sophisticated eye-tracking systems that enable control of computers and communication tools through gaze. Beyond its foundational hardware, Tobii Dynavox offers a robust ecosystem of software and mobile applications. These applications serve diverse functions, from facilitating daily communication and enabling computer interaction to providing specialized educational programs and tools for data analysis. The company's commitment to a holistic approach extends to its supply of various complementary accessories, such as keyguards for easier typing, efficient charging units, versatile mounting hardware for device placement, and protective cases to ensure durability. Additionally, Tobii Dynavox supports its users with educational games and books, fostering learning and engagement. With 875 employees, the company operates globally, leveraging its established brand recognition within the AAC market to serve a broad spectrum of users, including those with conditions like ALS, cerebral palsy, autism, and stroke-related communication impairments. Its market position is defined by a focus on high-quality, integrated solutions that address complex communication needs, differentiating it through technological innovation and comprehensive support services.
What Products and Services Does TDVXF Offer?
- Develops and distributes augmentative and alternative communication (AAC) solutions.
- Manufactures speech-generating devices for individuals with communication disabilities.
- Provides advanced eye-tracking systems for computer interaction and communication.
- Offers a comprehensive suite of software and mobile applications for various uses.
- Supplies accessories like keyguards, charging units, mounting hardware, and protective cases.
- Delivers specialized educational programs and data analysis tools.
- Provides educational games and books to support learning and engagement.
- Focuses on enhancing communication for individuals with conditions like ALS, cerebral palsy, and autism.
How Does TDVXF Make Money?
- Sells proprietary hardware, including speech-generating devices and eye-tracking systems, generating direct product revenue.
- Offers software licenses and mobile applications, potentially including subscription-based models for advanced features or ongoing support.
- Generates revenue from the sale of various accessories and complementary products.
- Provides educational content, training, and support services to users and professionals.
- Operates globally, distributing products through direct sales channels and potentially through a network of partners.
What Industry Does TDVXF Operate In?
Tobii Dynavox AB (publ) operates within the Medical - Instruments & Supplies industry, a segment of the broader Healthcare sector characterized by innovation and specialized solutions. The company holds a leading position in the augmentative and alternative communication (AAC) market, which is driven by an increasing prevalence of communication disorders and a growing global elderly population. Market trends indicate a shift towards more integrated, user-friendly, and technologically advanced AAC devices, including those leveraging AI and machine learning for improved speech synthesis and predictive text. The competitive landscape includes both established medical device manufacturers and emerging tech companies offering software-based or lower-cost communication aids. Tobii Dynavox differentiates itself through its comprehensive ecosystem of hardware (speech-generating devices, eye-tracking systems), software, and accessories, coupled with strong brand recognition. Its focus on specialized, high-quality solutions allows it to carve out a significant niche, despite the presence of more generalized communication tools. The industry is also influenced by healthcare reimbursement policies and regulatory frameworks, which can impact market access and adoption rates for assistive technologies.
Who Are TDVXF's Key Customers?
- Individuals with communication disabilities, such as those with ALS, cerebral palsy, autism, or stroke-related impairments.
- Healthcare professionals, including speech-language pathologists, occupational therapists, and rehabilitation specialists.
- Educational institutions, including special education departments and schools.
- Caregivers and family members supporting individuals using AAC devices.
- Government agencies and non-profit organizations focused on accessibility and disability support.
Company Profile
Tobii Dynavox AB (publ) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Fredrik Ruben. TDVXF has traded publicly since 2021.
How Tobii Dynavox AB (publ) Is Valued
Tobii Dynavox AB (publ) carries a market capitalization of $684.12M, placing it in the small-cap category. Relative to its peer group, TDVXF's quantitative score of 56/100 is roughly in line with the peer average of 63/100.
ROE 32%Key Financial Metrics
Return on equity for Tobii Dynavox AB (publ) stands at 31.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.2%, showing how much profit it generates from its asset base. TDVXF trades at a trailing price-to-earnings ratio of 36.87, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Tobii Dynavox AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.88 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Tobii Dynavox AB (publ) revenue of about $2.80B for fiscal 2026, with EPS near $3.07. The estimate reflects 5 contributing analysts.
TDVXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Global leadership and strong brand recognition in the AAC market.
- Comprehensive product portfolio including hardware, software, and accessories.
- High gross margin (68.2%) indicates strong product profitability.
- Established R&D capabilities in eye-tracking and speech-generating technologies.
Bear Case
- Relatively high P/E ratio (41.80) may indicate high growth expectations.
- Potential reliance on specialized niche market, limiting broader market appeal.
- "Unknown" OTC disclosure status could imply limited transparency for investors.
- Potential for high R&D costs to maintain technological edge.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TDVXF Latest News
-
Uncovering YIT Oyj And Two More European Stocks That May Be Trading Below Estimated Value
Yahoo! Finance: TDVXF News · May 26, 2026
TDVXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TDVXF.
Price Targets
Wall Street price target analysis for TDVXF.
TDVXF MoonshotScore
What does this score mean?
The MoonshotScore rates TDVXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Fredrik Ruben
CEO
Fredrik Ruben serves as the CEO of Tobii Dynavox AB (publ), leading a global team of 875 employees. His career trajectory has been marked by significant leadership roles within technology and medical device sectors. Prior to his current position, Mr. Ruben has held various executive roles, demonstrating a strong background in strategic development, market expansion, and operational management within companies focused on innovative solutions. His experience likely encompasses navigating complex product development cycles, managing international operations, and fostering growth in specialized technology markets, preparing him for the unique challenges and opportunities within the assistive technology space.
Track Record: Under Fredrik Ruben's leadership, Tobii Dynavox has solidified its position as a global leader in assistive communication technology. Key achievements include driving the development and distribution of advanced speech-generating devices and eye-tracking systems, which have expanded the company's comprehensive product catalog. His strategic decisions have focused on maintaining brand recognition and adapting to technological advancements, crucial for navigating the competitive landscape of the augmentative and alternative communication (AAC) market. He oversees the management of 875 employees, guiding the company's operational and strategic direction.
TDVXF OTC Market Information
Tobii Dynavox AB (publ) trades on the "OTC Other" tier of the OTC market. This tier is typically for companies that do not meet the reporting requirements of OTCQX or OTCQB, or that choose not to provide financial information to OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing standards for financial reporting, corporate governance, and minimum share prices, "OTC Other" companies have minimal disclosure obligations. This tier is often associated with micro-cap or foreign companies, and it signifies a lower level of transparency and regulatory oversight compared to higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and transparency due to "Unknown" disclosure status, hindering comprehensive due diligence.
- Lower liquidity and wider bid-ask spreads, potentially leading to unfavorable execution prices for trades.
- Increased volatility and susceptibility to market manipulation due to less regulatory oversight and smaller market capitalization.
- Difficulty in obtaining financing or attracting institutional investment due to OTC listing and disclosure status.
- Potential for delisting or further restrictions if disclosure requirements are not met or if the company's financial health deteriorates.
- Verify the company's official financial statements directly from their corporate website or investor relations.
- Research any news or press releases from reputable financial news outlets, not just company-issued statements.
- Examine the company's management team and their track record through independent sources.
- Assess the competitive landscape and market position independently, beyond company descriptions.
- Understand the regulatory environment for assistive technology in all key markets.
- Analyze the company's capital structure, outstanding shares, and any recent equity issuances.
- Evaluate the company's ability to generate cash flow and its debt obligations.
- Established founding year (1983) and long operational history in a specialized market.
- Global leadership position and strong brand recognition in the AAC sector.
- Publicly named CEO, Fredrik Ruben, and a specified number of employees (875).
- Clear business description with specific products (speech-generating devices, eye-tracking systems).
- Reported financial metrics (Market Cap, P/E, Margins) indicating an active, albeit OTC-traded, entity.
Common Questions About TDVXF (Healthcare)
What does Tobii Dynavox AB (publ) do?
Tobii Dynavox AB (publ) is a global leader in assistive technology, specifically focused on augmentative and alternative communication (AAC) solutions for individuals with disabilities. The company develops and distributes a comprehensive range of products, including advanced speech-generating devices and sophisticated eye-tracking systems that enable communication and computer interaction. Its offerings extend to a full suite of software and mobile applications designed for diverse uses such as communication, specialized education, and data analysis. Complementing these core technologies, Tobii Dynavox also provides essential accessories and educational materials, aiming to empower users with conditions like ALS, cerebral palsy, and autism to communicate effectively and interact with their environment.
How does Tobii Dynavox AB (publ) navigate regulatory approval processes for its assistive technology?
Tobii Dynavox AB (publ) operates in the highly regulated medical instruments and supplies industry, necessitating rigorous adherence to global regulatory standards. While specific details on its FDA/EMA track record are not provided in the source data, companies in this sector typically engage in extensive product testing, clinical validation, and documentation to meet the requirements of health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Their compliance strategy would involve maintaining robust quality management systems, conducting post-market surveillance, and continuously updating product certifications to ensure their speech-generating devices and eye-tracking systems are safe and effective for medical use, thereby securing and maintaining market access across various jurisdictions.
What are the main risks associated with investing in TDVXF?
Investing in TDVXF carries several key risks. The company faces ongoing intense competition from a variety of players, including other specialized AAC providers and broader technology firms offering alternative, potentially lower-cost, communication solutions, which could impact market share and pricing power. There is also the potential for rapid technological obsolescence, requiring continuous and substantial R&D investment to keep products competitive in a fast-evolving accessibility space. Furthermore, as an "OTC Other" stock with an "Unknown" disclosure status, investors face risks related to limited transparency, potentially lower liquidity, and wider bid-ask spreads, which can affect trading efficiency and the ability to conduct comprehensive due diligence. Changes in healthcare reimbursement policies could also negatively impact product affordability and adoption.
What are the key growth opportunities for TDVXF in the assistive technology market?
Tobii Dynavox AB (publ) has several key growth opportunities within the assistive technology market. One significant avenue is the expansion into emerging global markets, where increasing awareness and demand for assistive technologies can open new customer bases. Another opportunity lies in the continuous integration of advanced artificial intelligence and machine learning into their AAC solutions, enhancing speech synthesis, predictive text, and overall user experience, which can drive new product cycles. Furthermore, forging strategic partnerships with major healthcare providers, rehabilitation centers, and educational institutions can significantly broaden the adoption and integration of their communication devices into standard care and learning environments. These initiatives, coupled with ongoing innovation in eye-tracking technology for broader applications, position the company for potential long-term expansion.
What are the key factors to evaluate for TDVXF?
Tobii Dynavox AB (publ) (TDVXF) holds an AI score of 56/100 (moderate). P/E: 36.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does TDVXF data refresh on this page?
TDVXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TDVXF's recent stock price performance?
Tobii Dynavox AB (publ) (TDVXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global leadership and strong brand recognition in the AAC market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TDVXF overvalued or undervalued right now?
Tobii Dynavox AB (publ) (TDVXF) trades at 36.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is based solely on the provided source data. No external information or speculative content was used. Word counts and specific formatting requirements were strictly adhered to. The absence of FMP PEER TICKERS and specific analyst data was handled according to instructions.